Editor
The recently published 'French guidelines on the use of systemic treatments for moderate-to-severe psoriasis' provides a thorough overview and overall assessment of the therapeutic interventions currently available for psoriasis, including special considerations for patients with psoriatic arthritis (PsA).
We would like to inform that the interleukin-17A inhibitor ixekizumab is already approved for the treatment of active PsA in adults. This extended indication is based on the results from 2 randomized, double-blind, placebo-controlled phase 3 studies, SPIRIT-P1 and SPIRIT-P2, which included 780 adult patients with active PsA and demonstrated efficacy and safety of ixekizumab in both biologic na€ ıve and tumour necrosis factor inhibitor (TNFi)-experienced patients. In fact, the European Medicines Agency granted label extension of ixekizumab for PsA in January 2018 within 2 months following the end date of the literature search for the French guidelines.
Medicine is an ever-changing science, and psoriasis is a case in point highlighting the unprecedented speed of new and innovative developments. This makes regular and timely updates of guideline documents necessary to avoid loss of their clinical relevance as they age and newer research becomes available. Owing to the constantly changing therapeutic environment in psoriasis and reflecting current evidence, Amatore et al. modified the therapeutic algorithm of the European League Against Rheumatism (EULAR) for PsA to include ixekizumab. Similarly, the UK treatment guidelines for psoriasis are currently updated, already 2 years after their release pacing the rapidly growing number of approved therapeutics. We are confident and supportive of a similar approach for the French guidelines and look forward to the incorporation of additional data in the near future. 
